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of thrombosis and whether DAPT should be individualized according to stent type or
lesion or patient subsets is unknown. The Patient Related Outcomes with Endeavor versus
Cypher Stenting Trial (PROTECT) was designed and powered to compare long-term
outcomes of safety endpoints such as ST between the Endeavor zotarolimus-eluting stent
(E-ZES) and the Cypher sirolimus-eluting stent (C-SES).
Methods: PROTECT is a prospective, multicenter, randomized trial conducted at 196
sites in 36 countries worldwide in all continents. Patients with up to 4 coronary lesions
amenable for stenting were randomized to receive E-ZES or C-SES. The primary
endpoint is the 3 year rate of ARC-defined definite and probable ST. DAPT with
clopidogrel and aspirin were prescribed at least for 3 months and at physician discretion
for 12 months or longer. Planned and actual duration of DAPT, utilization of aspirin
(ASA) and clopidogrel by region, and aspirin dose (100mg, 100-300 mg, 300mg)
were collected. Multivariate regression analysis will be used to identify predictors for
DAPT duration of 12 months, DAPT compliance, and the relationship of these factors
with the outcomes of ST, myocardial infarction and cardiac death.
Results: PROTECT enrolled 8,800 patients; mean age 62.210.6 years and 76.3% were
male. Overall, 44.7% of patients presented with acute coronary syndromes, 27.2% had
diabetes mellitus, 20.5% prior MI, and 12.5% prior PCI. Almost all were de novo lesions
(98.2%), 46.6% in the left anterior descending artery and 54.8% were B2/C lesions.
Details of DAPT usage (planned and actual duration, ASA dosage) by region, and
according to patient characteristics will be available for presentation.
Conclusions: Analysis of the variation in duration of DAPT across regions and according
to patient characteristics in a real world setting will further our understanding of the
impact of DAPT on stent specific and global cardiovascular outcomes.
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Background: Platelet activation plays a critical role in the pathogenesis of acute
myocardial infarction (AMI). This study aimed to determine whether the results of platelet
function assays used to measure response to clopidogrel therapy are similar among
patients with stable CAD and those with AMI undergoing percutaneous coronary
intervention (PCI) both at the index admission and at 30 days’ post admission.
Methods: Sixty patients were prospectively enrolled into either an elective PCI cohort or
an AMI cohort. Patients presenting with an AMI were approached within 24 hours of
presentation and following PCI for participation. Patients underwent platelet function
testing post-PCI and again at 30 days ( 2 weeks) follow up. Tests included vasodilator
stimulated phosphoprotein phosphorylation (VASP) and VerifyNow P2Y12.
Results: The average age of the population was 64.5  11.2 years with no difference
between the elective and AMI groups. Baseline characteristics were similar, with an
overall rate of diabetes of 26.7%, hypertension 78.3%, current smokers 15.0%, prior CAD
35.0%, renal insufficiency 6.7% and the average BMI was 31  7. The AMI group had
higher PRU, percent inhibition, and PRI at the time of PCI as compared to the elective PCI
group. This difference was not sustained at 30 days. The PRU significantly decreased at
30 days compared to the PCI procedure for the AMI group. Similarly, the percent
inhibition and PRI decreased, but did not achieve statistical significance. (Table).
Conclusions: Platelet reactivity is higher at the time of primary PCI (vs. elective PCI)
with AMI presentation. These data support the notion that the platelets become
hypersensitive at the time of AMI and are passivated over time given antiplatelet therapy.
The on-treatment platelet reactivity should be assessed for patients presenting with AMI
to appropriately tailor the antiplatelet regime.
Elective AMI P Value
Index Procedure
PRU 159.13	/ 93.01 202.97	/ 99.85 0.095
Percent Inhibition 45.57	/ 30.03 23.73	/ 29.86 0.008
VASP-PRI 30.40	/ 24.03 52.63	/ 20.02 0.001
Platelet count 196.19	/ 66.86 218.46	/ 63.70 0.201
AST 27.55	/ 24.88 90.92	/ 88.36 0.002
30 Days Follow
Up
PRU 180.00	/ 93.64 189.52	/ 86.86 0.738
Percent Inhibition 38.28	/ 30.00 31.61	/ 26.94 0.459
VASP-PRI 41.79	/ 22.60 47.92	/ 23.76 0.407
Platelet count 235.35	/ 72.56 243.61	/ 50.50 0.673
Index Procedure 30 Days Follow Up P Value (paired)
Elective
PRU 159.13	/ 93.01 180.00	/ 93.64 0.125
Percent Inhibition 45.57	/ 30.03 38.28	/ 30.00 0.445
VASP-PRI 30.40	/ 24.03 41.79	/ 22.60 0.032
Platelet count 196.19	/ 66.86 235.35	/ 72.56 0.009
AMI
PRU 202.97	/ 99.85 189.52	/ 86.86 0.003
Percent Inhibition 23.73	/ 29.86 31.61	/ 26.94 0.195
VASP-PRI 52.63	/ 20.02 47.92	/ 23.76 0.349
Platelet Count 218.46	/ 63.70 243.61	/ 50.50 0.001
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Background: In patients with ST elevation myocardial infarction (STEMI) undergoing
primary percutaneous coronary intervention (pPCI) ticagrelor 180mg loading dose (LD)
exhibits a delayed onset of action – from what would be predicted based on assessments
in stable patients. Since Cmax for ticagrelor and its main metabolite increases approxi-
mately dose-proportionately, we hypothesized that doubling the ticagrelor LD in patients
with STEMI undergoing pPCI may lead to faster early platelet inhibition.
Methods: This is a prospective, pharmacodynamic study in P2Y12 inhibitor naïve
patients with STEMI (onset of pain12 hours) undergoing pPCI. Patients after informed
consent received 360mg LD of ticagrelor immediately before pPCI. Platelet reactivity
(PR) was assessed with VerifyNow assay in platelet reactivity units (PRU) immediately
before LD (Hour 0) and at 0.5, 1, 2 and Hour 4 after LD.
Results: Data of 24 patients are presented (79.2%men, mean age 54.79.5 years). At
hour 0 mean PR was 226.866.8 PRU. At hour 0.5, 1, 2 and 4 PR was 272.4 (252.0-292.7
95% CIs), 227.3 (190.2-264.4 95%CIs), 134.7 (85.0-184.3 95%CIs) and 56.8(24.1-89.4
95%CIs) respectively. A statistical significant reduction in PR was observed between
Hour 0 and Hour 2, with a mean difference of -89.9 PRU (-15.1 to -164.8 95%CIs,
p0.01). A statistical significant increase in PR was observed between Hour 0 and Hour
0.5, with a mean difference of 47.8 PRU (17.2 to 78.5 95% CIs, p0.001) PR mean
difference between Hour 1-Hour 2 and Hour 2-Hour 4 was also significant (-92.6 PRU,
-159.8 to -25.4 95%CIs, p0.003 and -77.9 PRU, -135.3 to -20.5, p0.004). No major
adverse cardiovascular events or bleeding events observed until discharge.
Conclusions: In P2Y12 inhibitors naïve STEMI patients undergoing pPCI, an initial
delay in the onset of ticagrelor’s antiplatelet action until Hour 1 is observed, despite the
doubling of the loading dose.
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Background: No data exit regarding the association between aspirin / clopidogrel
resistance and intra-stent thrombi on follow-up optical coherence tomography (OCT)
following drug-eluting stents (DES) implantation. So we measured the presence of
intra-stent thrombi in OCT and aspirin reaction unit (ARU), P2Y12 reaction unit (PRU),
inhibition ratio of PRU in patients with drug eluting stent (DES).
Methods: From our OCT registry, a total of 313 patients treated with DES underwent
follow-up OCT and performed the measurement of aspirin reaction unit (ARU), P2Y12
reaction unit (PRU), inhibition ratio of PRU using VerifyNow (VN) on the same day for
follow-up OCT. Aspirin and clopidogrel resistance were defined as ARU550 and PRU
250, respectively. For assessing whether aspirin / clopidogrel resistance could be related
to intra-stent thrombi on OCT, we divided the patients according to the presence of aspirin
or clopidogrel resistance, and then compared the occurrence of intra-stent thrombi on
OCT between the patients with or without resistance.
Results: Mean OCT follow-up duration of enrolled 313 patients was 195133 days.
According to the presence of aspirin / clopidogrel resistance, there was no significant
difference in the occurrence of intra-stent thrombi on OCT. On the assessment according
to the major risk factors of coronary artery disease, there was also no significant difference
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as shown in the table. Multivariate logistic regression analysis, DM was independent
predictor of intra-stent thrombi on OCT (OR 14.031, 95% CI 2.556-77.033, p0.002),
adjusting ARU, PRU and major risk factors, but ARU, PRU and aspirin / clopidogrel
resistance were not related to intra-stent thrombi on OCT.
Conclusions: This OCT study demonstrated that ARU, PRU and aspirin / clopidogrel
resistance were not related to intra-stent thrombi on OCT.
All Patients (n313) p DM (n94) P
AR (	) 3 (8.6%) 0.288 2 (11.1%) 1.000
AR () 12 (4.4%) 8 (11.1%)
CR (	) 5 (3.0%) 0.107 5 (8.8%) 0.466
CR () 10 (7.0%) 5 (13.5%)
HTN (n184) p Age>75 (n18) p
0 0.341 0 1.000
8 (4.8%) 1 (7.1%)
5 (4.6%) 0.823 1 (7.7%) 1.000
3 (3.9%) 0
OCT-D>6month (n170) p
3 (11.1%) 0.408
9 (6.3%)
3 (3.9%) 0.234
9 (9.2%)
AR : Aspirin resistance (ARU550), CR ; Clopidogrel resistance (PRU250), DM ; Diabetes
mellitus, HTN ; Hypertension, OCD-D ; OCT follow-up duration, p ; p-value
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Background: Although high on-treatment platelet reactivity (HoTPR) predicts future
ischemic events after percutaneous coronary intervention (PCI), the clinical applicability
of platelet function testing remain unclear. This study aims to evaluate the impact of
platelet function testing results on the managing physician’s response to escalate
antiplatelet therapy after PCI.
Methods: The study included 465 consecutive patients undergoing PCI who were on5
days of maintenance clopidogrel therapy. We performed platelet function testing with the
Verify Now P2Y12 (Accumetrics) assay before the PCI. The result of this assay was made
known to the managing physician after PCI. HoTPR was defined as230 P2Y12 reaction
units (PRU). Antiplatelet therapy at baseline and at hospital discharge post-PCI was
recorded. We also evaluated the 30-day major adverse clinical events (MACE: all-cause
mortality, myocardial infarction, and target vessel revascularization) in this population.
Results: The mean age of the study population was 63 years; 73% were male and 22%
were African-American. HoTPR was present in 143 patients (30.8%). Of these, only
21(14.7%) were managed with an escalation of antiplatelet therapy (increased clopidogrel
dose or switched to prasugrel). Of the remaining 322 patients with appropriate platelet
inhibition of230PRU, 55 (17.1%) received more intensive antiplatelet therapy. Patients
more likely to receive intensified antiplatelet therapy were those with a history of coronary
artery bypass grafting (p0.03), diabetes mellitus (p0.03), and dialysis (p0.04), as
well as those presenting with myocardial infarction (p0.014), receiving vein-graft PCI
and treatment to a complex (ACC/AHA type C) lesion. At 30 days, 4 MACE events
occurred. The group with HoTPR who received intensified antiplatelet therapy had the
highest proportion of events (4.7% vs 2.2%, p0.04).
Conclusions: The results of platelet function testing do not significantly impact decisions
to alter amtiplatelet therapy post-PCI. Rather, baseline clinical and angiographic param-
eters were primary factors considered when intensifying antiplatelet therapy.
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Background: ADP-specific platelet function assays were shown to predict thrombotic
events, and might be helpful to select candidates for more potent antiplatelet therapy. We
aimed to determine the efficacy and safety of giving intensified antiplatelet therapy on the
basis of platelet reactivity testing for patients undergoing percutaneous coronary inter-
vention (PCI).
Methods: Electronic databases were searched to find prospective, randomized trials that
reported the clinical impact of using an intensified antiplatelet protocol (repeated loading
or elevated maintenance doses of clopidogrel, prasugrel or glycoprotein IIb/IIIa inhibitor)
on the basis of ADP-specific platelet reactivity testing (using VerifyNow, Multiplate,
VASP or light transmission aggregometry) compared to standard-dose clopidogrel.
Evaluated efficacy measures included cardiovascular death, non-fatal myocardial infarc-
tion and definite/probable stent thrombosis (ST), while major bleeding events were
recorded as safety endpoint.
Results: Between 2008 and 2011, 10 clinical trials comprising 4,213 randomized patients
were identified. Compared to standard antiplatelet therapy, the intensified protocol was
associated with a significant reduction in cardiovascular mortality, ST and myocardial
infarction (p0.01 for all). There was no difference in the rate of major bleeding events
between intensified and standard groups (P0.44). Although the observed effects
regarding mortality, ST and bleeding were not heterogeneous, meta-regression analysis
revealed that the net clinical benefit of the more potent antiplatelet strategy in patients with
HPR significantly depended on the risk of ST of the control group using standard-dose
clopidogrel (p0.023).
Conclusions: Intensifying antiplatelet therapy on the basis of platelet reactivity testing
might reduce cardiovascular mortality and ST after PCI, without increasing major
bleeding complications. However, the net benefit of giving more potent agents based on
platelet function testing depends on the risk of ST with standard-dose clopidogrel.
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Background: The potential negative metabolic interaction between proton pump
inhibitors (PPI) and clopidogrel is of particular concern. We have hypothesized that
doubling the maintenance dose (MD) of clopidogrel (150mg, double) was less effective
than switching to prasugrel 10mg MD (switch) to attenuate this potential negative
interaction.
Methods: In a prospective randomized placebo-controlled double blind study, we
assigned 82 stable coronary artery disease patients treated with 75 mg clopidogrel MD
dose and aspirin to receive lanzoprazole (30mg/day) or placebo in addition to either
clopidogrel double MD (150 mg/jour) or standard prasugrel MD (10 mg/jour). The
primary endpoint was the relative change in residual platelet reactivity (RPA, assessed by
light transmission aggregometry, 20Mol ADP) over the 14 days study period [(RPA-
baseline-RPA14day)/RPAbaseline]. All the measures were performed 4 hours after drug
intake. Exclusion criteria were instability, contraindication to prasugrel and a mandatory
use of PPI.
Results: Baseline characteristics were balanced between the 4 groups. The effect of a
double clopidogrel MD on RPA was significantly blunted by the co-administration of
lansoprazole (-53.648.6% versus 0.853.7% without and with lansoprazole, respec-
tively, p0.001) whereas 10 mg of prasugrel MD dramatically reduced RPA irrespective
of lanzoprazole co-administration (-81.824.8% versus -72.932.9%, without and with
lanzoprazole, respectively, pNS). In patients receiving double clopidogrel MD and
lansoprazole, RPA was not significantly different from that of clopidogrel 75mg MD
alone. These findings were consistent irrespective of the platelet function test used to
assess RPA. PPI use was the only parameter with a significant interaction with RPA
among clopidogrel groups. CYP2C19 metabolizer status displayed non-significant inter-
action with RPA irrespective of the thienopyridine strategy.
Conclusions: The effect of a double clopidogrel MD on platelet inhibition is significantly
attenuated by the co-administration of lansoprazole as opposed to prasugrel 10mg.
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